BioSpace News Archive

Oncopeptides AB, announced new data presented at the 24th Congress of the European Hematology Association in Amsterdam, including updated interim data from the ongoing phase 1/2 ANCHOR study and data from its phase 1/2 O-12-M1 study.

OneFifteen celebrates its grand opening in Dayton, Ohio -- a city once known for its rich history of innovation, but now at the center of the national opioid epidemic -- with the goal to reduce opioid overdose deaths and contribute to the vitality and well-being of the community

In patients who were at least six months post-treatment with LentiGlobin for SCD, median level of abnormal sickle hemoglobin (HbS) was reduced to ≤50 percent of total Hb

BerGenBio ASA presents data showing significant efficacy in a Phase II clinical trial evaluating bemcentinib, a first-in-class selective oral AXL inhibitor, in combination with low-dose cytarabine as a potential new treatment regimen for AML patients unfit for intensive therapy.

MEDNAX, Inc., announced its affiliation with Alfredo Gei MD, P.A., a private maternal-fetal medicine practice based in Houston.

Aura Biosciences announced that interim clinical data from its ongoing Phase 1b/2 clinical trial evaluating the safety and efficacy of light-activated AU-011, the Company’s lead product candidate for the treatment of primary choroidal melanoma, will be highlighted in an oral presentation at the European Society of Ophthalmology 2019 Congress being held June 13-16, 2019, in Nice, France.

Canopy Growth Corporation and Acreage Holdings, Inc. thank shareholders for their overwhelming support to date and remind shareholders to vote on the applicable resolutions in connection with the proposed acquisition of Acreage by Canopy Growth, before the voting deadline of 10:00 am on Monday, June 17, 2019.

First and only once-daily, nebulized bronchodilator has potential to address unmet needs of China’s nearly 100 million chronic obstructive pulmonary disease (COPD) patients [14-June-2019] DUBLIN and HERTFORDSHIRE, England and PITTSBURGH , June 14, 2019 /PRNewswire/ -- Theravance Biopharma Ireland Limited, a subsidiary of Theravance Biopharma, Inc. (NASDAQ: TBPH) (

Applied DNA Sciences, Inc. (NASDAQ: APDN), announced today that its scientific paper entitled, ‘Rapid authentication of pharmaceuticals via DNA tagging and field detection’, has been published in the June 2019 edition of PLOS ONE, detailing a novel Physical-Chemical Identifier (PCID) to authenticate and track legitimate pharmaceutical products through the pharmaceutical supply chain.

Reistone Biopharma Company Limited (Reistone) announced today dosing of the first patient in their Phase II global clinical trials (RSJ10101 and RSJ10201) of SHR0302 in patients with Ulcerative Colitis and Crohn’s disease respectively